Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Change in Cash (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Change in Cash for 11 consecutive years, with $499.1 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 768.32% to $499.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 billion through Dec 2025, up 460.15% year-over-year, with the annual reading at $2.0 billion for FY2025, 460.15% up from the prior year.
  • Change in Cash for Q4 2025 was $499.1 million at BeOne Medicines, down from $1.3 billion in the prior quarter.
  • The five-year high for Change in Cash was $3.4 billion in Q4 2021, with the low at -$397.0 million in Q3 2021.
  • Average Change in Cash over 5 years is $180.5 million, with a median of -$91.4 million recorded in 2024.
  • The sharpest move saw Change in Cash skyrocketed 4344.29% in 2021, then tumbled 1064.93% in 2023.
  • Over 5 years, Change in Cash stood at $3.4 billion in 2021, then plummeted by 109.62% to -$325.5 million in 2022, then surged by 132.29% to $105.1 million in 2023, then crashed by 171.06% to -$74.7 million in 2024, then skyrocketed by 768.32% to $499.1 million in 2025.
  • According to Business Quant data, Change in Cash over the past three periods came in at $499.1 million, $1.3 billion, and $255.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.